A phase II study of atezolizumab immunotherapy met its primary endpoint, shrinking tumors in patients with locally advanced or metastatic non-small cell lung cancer whose disease expressed PD-L1.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
